(AOF) – Orapi revealed a group share loss of 18.8 million euros for its 2023 annual results compared to a net profit of 800,000 euros in 2022. The manufacturer of high-tech products and solutions for hygiene and industrial maintenance published an Ebitda of 16.3 million euros compared to 16 million euros a year earlier and 19.8 million in 2021. Its turnover of 229.1 million euros appears down 0.2% compared to 2022 at current scope.
The management board, newly composed since December 22, 2023, takes note of the 2023 results, significantly below the objectives planned by the “Orapi 2025” Plan, which is now obsolete.
This same management board has initiated an in-depth diagnosis “which should enable it to initiate a 3-year turnaround plan, with the main objective of returning to a positive net result”, according to a press release.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.